ATE497389T1 - Aus stammzellen erhaltener parakriner faktor h12 zur verwendung für die verringerung zelltodes oder für die reparatur von gewebe - Google Patents

Aus stammzellen erhaltener parakriner faktor h12 zur verwendung für die verringerung zelltodes oder für die reparatur von gewebe

Info

Publication number
ATE497389T1
ATE497389T1 AT06802032T AT06802032T ATE497389T1 AT E497389 T1 ATE497389 T1 AT E497389T1 AT 06802032 T AT06802032 T AT 06802032T AT 06802032 T AT06802032 T AT 06802032T AT E497389 T1 ATE497389 T1 AT E497389T1
Authority
AT
Austria
Prior art keywords
cell death
factor
tissue
paraccrine
repair
Prior art date
Application number
AT06802032T
Other languages
English (en)
Inventor
Victor Dzau
Mirotsou Maria
Jian Guo
Arjun Deb
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE497389T1 publication Critical patent/ATE497389T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
AT06802032T 2005-08-19 2006-08-21 Aus stammzellen erhaltener parakriner faktor h12 zur verwendung für die verringerung zelltodes oder für die reparatur von gewebe ATE497389T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71002805P 2005-08-19 2005-08-19
US71128705P 2005-08-25 2005-08-25
PCT/US2006/032656 WO2007022515A2 (en) 2005-08-19 2006-08-21 Stem cell derived factors for treating pathologic conditions

Publications (1)

Publication Number Publication Date
ATE497389T1 true ATE497389T1 (de) 2011-02-15

Family

ID=37758496

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06802032T ATE497389T1 (de) 2005-08-19 2006-08-21 Aus stammzellen erhaltener parakriner faktor h12 zur verwendung für die verringerung zelltodes oder für die reparatur von gewebe
AT08005943T ATE499110T1 (de) 2005-08-19 2006-08-21 Aus stammzellen erhaltener parakriner faktor sfrp1 zur verwendung für die verringerung zelltodes im herzgewebe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT08005943T ATE499110T1 (de) 2005-08-19 2006-08-21 Aus stammzellen erhaltener parakriner faktor sfrp1 zur verwendung für die verringerung zelltodes im herzgewebe

Country Status (6)

Country Link
US (6) US7638128B2 (de)
EP (4) EP1940445B1 (de)
AT (2) ATE497389T1 (de)
CA (2) CA2619593C (de)
DE (2) DE602006019974D1 (de)
WO (1) WO2007022515A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5025646B2 (ja) * 2005-11-08 2012-09-12 公益財団法人先端医療振興財団 虚血性心疾患の治療方法
GB0707348D0 (en) * 2007-04-17 2007-05-23 Renovo Ltd Medicaments and methods for inhibition of scarring
CA2704627A1 (en) * 2007-11-04 2009-05-07 Duke University Compositions for tissue repair/regeneration
WO2009085216A2 (en) 2007-12-20 2009-07-09 Squicor Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2009132815A1 (en) 2008-04-30 2009-11-05 Roche Diagnostics Gmbh Use of sfrp-3 in the assessment of heart failure
GB0818725D0 (en) * 2008-10-13 2008-11-19 Habib Nagy A Pharmaceutical composition
CA2755396A1 (en) * 2009-03-13 2010-09-16 Duke University Use of hasf as a protective agent against ischemic tissue damage
US20120107413A1 (en) * 2009-07-23 2012-05-03 Singapore Health Services Pte Ltd Pre-natal mesenchymal stem cells
JP5409222B2 (ja) * 2009-09-10 2014-02-05 学校法人慶應義塾 造血幹細胞の培養方法
EP2723364A1 (de) 2011-06-24 2014-04-30 National University of Ireland Galway Zellsekretierte proteine zur behandlung von herzinfarkten
US9950032B2 (en) * 2011-10-27 2018-04-24 Agency For Science, Technology And Research (A*Star) Compositions and methods for lung regeneration
EP2879682B1 (de) 2012-08-01 2018-03-21 United Therapeutics Corporation Behandlung von pulmonal-arteriellem hochdruck mit mesenchymalen stammzellen
KR102143961B1 (ko) 2012-08-01 2020-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린-처리된 내피 전구 세포를 사용한 폐동맥 고혈압의 치료
ES2697573T3 (es) * 2013-01-09 2019-01-25 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas
CN105561338A (zh) * 2015-05-14 2016-05-11 首都医科大学附属北京口腔医院 Sfrp2在促进牙源性间充质干细胞成骨/成牙分化中的应用
WO2018064315A1 (en) * 2016-09-29 2018-04-05 North Carolina State University Stem cell biomimetic microparticles
JP7179723B2 (ja) 2016-10-24 2022-11-29 ユナイテッド セラピューティクス コーポレイション トレプロスチニルによるｍｓｃの免疫調節特性の増強
WO2022066714A2 (en) * 2020-09-22 2022-03-31 Children's Medical Center Corporation Delivery of sfrp-3 or foxm1 inhibitor to protect from and treat mitral regurgitation and heart failure

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433155B1 (en) * 1996-09-24 2002-08-13 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
CA2331386A1 (en) * 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
WO2003080795A2 (en) * 2001-08-09 2003-10-02 Nuvelo Inc. Novel nucleic acids and secreted polypeptides
WO2003062376A2 (en) * 2002-01-16 2003-07-31 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
US20040258669A1 (en) * 2002-11-05 2004-12-23 Dzau Victor J. Mesenchymal stem cells and methods of use thereof
WO2004053069A2 (en) * 2002-12-06 2004-06-24 The Board Of Trustees Of The Leland Stanford Junior University PROTECTION OF STEM CELLS FROM CYTOTOXIC AGENTS BY MODULATION OF β-CATENIN SIGNALING PATHWAYS
WO2004087874A2 (en) * 2003-03-28 2004-10-14 Nuvelo, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
DE602006020349D1 (de) 2011-04-07
US20140357703A1 (en) 2014-12-04
DE602006019974D1 (de) 2011-03-17
EP1977758A2 (de) 2008-10-08
EP2226079B1 (de) 2012-07-11
US8703710B2 (en) 2014-04-22
EP2548569A1 (de) 2013-01-23
US20070259425A1 (en) 2007-11-08
WO2007022515A9 (en) 2007-05-10
WO2007022515A2 (en) 2007-02-22
CA3022238A1 (en) 2007-02-22
CA2619593A1 (en) 2007-02-22
EP2226079A2 (de) 2010-09-08
ATE499110T1 (de) 2011-03-15
US7638128B2 (en) 2009-12-29
US20120283183A9 (en) 2012-11-08
EP1977758B1 (de) 2011-02-23
EP1940445A4 (de) 2008-10-15
US20170128526A1 (en) 2017-05-11
US20080176207A1 (en) 2008-07-24
EP1940445B1 (de) 2011-02-02
US9353168B2 (en) 2016-05-31
US9279012B2 (en) 2016-03-08
EP1940445A2 (de) 2008-07-09
US8129344B2 (en) 2012-03-06
US20140296152A1 (en) 2014-10-02
EP2548569B1 (de) 2014-01-29
CA2619593C (en) 2018-12-11
EP1977758A3 (de) 2009-01-07
US20110003743A1 (en) 2011-01-06
WO2007022515A3 (en) 2008-02-28
EP2226079A3 (de) 2010-12-08

Similar Documents

Publication Publication Date Title
ATE497389T1 (de) Aus stammzellen erhaltener parakriner faktor h12 zur verwendung für die verringerung zelltodes oder für die reparatur von gewebe
DE60228460D1 (de) Verfahren zur Herstellung und Reinigung von Erythropoietin
ATE470702T1 (de) Verfahren zur herstellung von permanenten humanen zelllinien
ATE518496T1 (de) Verfahren zur gewinnung von lebensfähigen kleinen gewebeteilchen und ihre verwendung für die gewebereparatur
EP2342333A4 (de) Verfahren zur herstellung induzierter pluripotenter stammzellen
ATE513788T1 (de) Verfahren zur reinigung von lithiumsulfid
BRPI0514680A (pt) produção de anticorpos anti-amilóide beta
DE602005023332D1 (de) Kollagenproduzierende pflanzen sowie verfahren zu deren erzeugung und verwendung
ATE522233T1 (de) Vorbereitung von gewebe für die meniskus- implantation
EA200401591A1 (ru) Керамические аноды и способ их изготовления
WO2006017134A3 (en) Preprimitive streak and mesendoderm cells
BR122019022434B8 (pt) método para cultivar células de mamífero que secretam proteína heteróloga em um sobrenadante de cultura celular
ZA200800517B (en) Transplastomic plants expressing lumen-targeted protein
AR063972A1 (es) Plantas con rasgos mejorados relacionados con el rendimiento y un metodo para producirlas
ATE556716T1 (de) Verwendung des luteinisierenden hormons (lh) und von choriongonadotrophin (hcg) für die proliferation von neuralen stammzellen und neurogenese
WO2007106200A3 (en) Expansion and differentiation of neural stem cells under low oxygen conditions
ATE513934T1 (de) Stahl für eine form zur kunststoffformung und form zur kunststoffformung
BRPI0811235A2 (pt) Processo de preparação de uma vermiculita exfoliada e de fabricação de um material comprimido.
EP1718733A4 (de) Zusammensetzungen und verfahren in verbindung mit der kultivierung neuraler stammzellen mit knochenmarksstromazellen
BR112012011816A2 (pt) processo para preparar um catalisador de hidrogenação suportado com atividade de hidrogenção aumentada, catalisador de hidrogenação suportado, uso do mesmo, e, processo para a hidrogenação de compostos orgânicos
ATE449608T1 (de) Verwendung von cxcl6 chemokin bei der prävention oder reparatur von knorpeldefekten
DE602006017223D1 (de) Biologische materialien und verwendungen davon
WO2011005974A3 (en) Interpenetrating biomaterial matrices and uses thereof
ATE541045T1 (de) Enzymatisches verfahren zur herstellung bioaktiver, osteoblasten-stimulierender oberflachen und verwendung derselben
CR11725A (es) Método para la producción de una enzima lisosomal recombinante humana en endoesperma de cereal

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties